1 min to read News Posted on March 13, 2023 Moody's affirms Pfizer's A1 rating; revises outlook to negative – Moody's Moody's affirms Pfizer's A1 rating; revises outlook to negative Moody's Source: Moody's affirms Pfizer's A1 rating; revises outlook to negative – Moody's share tweet share Tags: SPACs